Los puntos clave no están disponibles para este artículo en este momento.
After the team behind Karuna Therapeutics sold the firm in December for 14 billion, some members of that same group have started another biotechnology firm developing neuropsychiatric drugs. Boston-based Seaport Therapeutics launched April 9 with 100 million in an oversubscribed series A financing round led by Arch Venture Partners and Sofinnova, along with Third Rock Ventures and Seaport and Karuna founder PureTech Health. Daphne Zohar, former CEO of PureTech Health, will serve as Seaport's CEO, and Steven M. Paul, former CEO of Karuna, will chair Seaport's board of directors. Seaport's core is its Glyph platform, which is based on work by Chris Porter of Monash University. The platform uses a glyceride moiety to divert drugs, bypassing the liver to dramatically boost bioavailability as well as decrease toxicity. Seaport launches with a trio of lead candidates. "We picked three drugs that we believe are going to be really effective, but
special to C EN Alla Katsnelson (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: